Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Albumin domain II mutant with high bilirubin binding affinity has a great potential as serum bilirubin excretion enhancer for hyperbilirubinemia treatment

    Access Status
    Fulltext not available
    Authors
    Minomo, Ai
    Ishima, Yu
    Chuang, Victor
    Suwa, Yoshiaki
    Kragh-Hansen, Ulrich
    Narisoko, Toru
    Morioka, Hiroshi
    Maruyama, Toru
    Otagiri, Masaki
    Date
    2013
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Minomo, Ai and Ishima, Yu and Chuang, Victor and Suwa, Yoshiaki and Kragh-Hansen, Ulrich and Narisoko, Toru and Morioka, Hiroshi and Maruyama, Toru and Otagiri, Masaki. 2013. Albumin domain II mutant with high bilirubin binding affinity has a great potential as serum bilirubin excretion enhancer for hyperbilirubinemia treatment. Biochimica et Biophysica Acta. 1830 (4): pp. 2917-2923.
    Source Title
    Biochimica et Biophysica Acta - General Subjects
    DOI
    10.1016/j.bbagen.2013.01.006
    ISSN
    03044165
    URI
    http://hdl.handle.net/20.500.11937/18060
    Collection
    • Curtin Research Publications
    Abstract

    Background: 4Z,15Z-bilirubin-IXα (BR), an endogenous toxic compound that is sparingly soluble in water, binds human serum albumin (HSA) with high affinity in a flexible manner. Our previous findings suggest that both Lys195 and Lys199 in subdomain IIA are important for the high-affinity binding of BR, and especially Lys199 in stand-alone domain II plays a prominent role in the renal elimination of BR. Our hypothesis is that HSA-domain II with high BR binding would be a useful therapeutic agent to treat hyperbilirubinemia in patients with impaired liver function. Methods: Unbound BR concentrations were determined using a modified HRP assay. To evaluate the effect of pan3_3-13 domain II mutant in promoting urinary BR excretion, the serum concentration and urinary excretion amount of BR were determined using bile duct ligation mice. Results: After three or six rounds of panning, pan3_3-13 and pan6_4 were found to have a significantly higher affinity for BR than wild-type domain II. Administration of pan3_3-13 significantly reduced serum BR level and increased its urinary excretion in the disease model mice as compared to wild-type domain II treatment. Conclusions: These results suggest that pan3_3-13 has great potential as a therapeutic agent that promotes urinary BR excretion in hyperbilirubinemia.

    Related items

    Showing items related by title, author, creator and subject.

    • Urolithiasis: occurrence and function of intracrystalline proteins in calcium oxalate monohydrate crystals
      Fleming, David Elliot (2004)
      The broad aim of the work presented in this thesis was to examine the relationship between the mineral and organic phases of calcium oxalate monohydrate (COM) crystals, which are the principal components of human kidney ...
    • Molecular modelling of platelet endothelial cell adhesion molecule 1 and its interaction with glycosaminoglycans
      Gandhi, Neha Sureshchandra (2007)
      The Platelet Endothelial Cell Adhesion Molecule 1 (PECAM-1) has many functions including its roles in leukocyte extravasation as part of the inflammatory response, and in the maintenance of vascular integrity through its ...
    • The effects of a two-year randomised controlled trial of whey protein supplementation on bone structure, IGF-I and urinary calcium excretion in older postmenopausal women.
      Zhu, K.; Meng, X.; Kerr, Deborah; Devine, A.; Solah, Vicky; Binns, Colin; Prince, R. (2011)
      The effects of dietary protein on bone structure and metabolism have been controversial with evidence for and against beneficial effects. Because no long-term randomised controlled studies have been performed, a two-year ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.